Table S1.
Details on goodness of fit with the KM curves and survival rates of letrozole monotherapy from MONALEESA-2 study (reference arm)
| Parameterization of the PFS KM curves
| ||||
|---|---|---|---|---|
| Distribution | Goodness of fit
|
PFS rate (%)
|
||
| AIC | BIC | 5 years | 10 years | |
|
| ||||
| Exponential | 1,693.30 | 1,697.11 | 6.79 | 0.46 |
| Weibull | 1,689.87 | 1,697.49 | 3.93 | 0.07 |
| Gamma | 1,689.11 | 1,696.73 | 4.53 | 0.15 |
| Gompertz | 1,692.06 | 1,699.68 | 1.97 | 0.00 |
| Log-normal | 1,688.60 | 1,696.22 | 12.16 | 4.07 |
| Log-logistic | 1,692.66 | 1,700.29 | 12.19 | 4.90 |
|
| ||||
| Parameterization of the OS KM curves | ||||
|
| ||||
| Distribution |
Goodness of fit
|
OS rate (%)
|
||
| AIC | BIC | 5 years | 20 years | |
|
| ||||
| Exponential | 763.63 | 767.44 | 60 | 13.0 |
| Weibull | 733.69 | 741.31 | 26 | 0.0 |
| Gamma | 735.99 | 743.61 | 37 | 0.1 |
| Gompertz | 729.74 | 737.36 | 4 | 0.0 |
| Log-normal | 741.89 | 749.51 | 49 | 7.8 |
| Log-logistic | 735.52 | 743.14 | 38 | 2.8 |
Abbreviations: AIC, Akaike information criteria; BIC, Bayesian information criteria; KM, Kaplan–Meier; OS, overall survival; PFS, progression-free survival.